- Home
- LPCN vs CLGN Comparison
LPCN vs CLGN Comparison
Compare LPCN & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- CLGN
- Stock Information
- Founded
- LPCN 1997
- CLGN 2004
- Country
- LPCN United States
- CLGN Israel
- Employees
- LPCN N/A
- CLGN N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- LPCN Health Care
- CLGN Health Care
- Exchange
- LPCN Nasdaq
- CLGN Nasdaq
- Market Cap
- LPCN 16.1M
- CLGN 19.1M
- IPO Year
- LPCN N/A
- CLGN N/A
- Fundamental
- Price
- LPCN $2.95
- CLGN $2.98
- Analyst Decision
- LPCN Strong Buy
- CLGN Strong Buy
- Analyst Count
- LPCN 2
- CLGN 2
- Target Price
- LPCN $9.00
- CLGN $11.50
- AVG Volume (30 Days)
- LPCN 36.3K
- CLGN 51.9K
- Earning Date
- LPCN 08-05-2025
- CLGN 08-20-2025
- Dividend Yield
- LPCN N/A
- CLGN N/A
- EPS Growth
- LPCN N/A
- CLGN N/A
- EPS
- LPCN N/A
- CLGN N/A
- Revenue
- LPCN $4,208,119.00
- CLGN $2,472,000.00
- Revenue This Year
- LPCN N/A
- CLGN $1,999.42
- Revenue Next Year
- LPCN N/A
- CLGN $69.81
- P/E Ratio
- LPCN N/A
- CLGN N/A
- Revenue Growth
- LPCN N/A
- CLGN N/A
- 52 Week Low
- LPCN $2.68
- CLGN $1.31
- 52 Week High
- LPCN $6.17
- CLGN $5.45
- Technical
- Relative Strength Index (RSI)
- LPCN 37.54
- CLGN 73.73
- Support Level
- LPCN $2.92
- CLGN $2.14
- Resistance Level
- LPCN $3.25
- CLGN $2.97
- Average True Range (ATR)
- LPCN 0.19
- CLGN 0.28
- MACD
- LPCN -0.04
- CLGN 0.06
- Stochastic Oscillator
- LPCN 4.41
- CLGN 97.67
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.